N
KLRA

Nuveen’s Kailera Therapeutics KLRA Stock Holding History

Nuveen’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
+88,796
New +$1.95M ﹤0.01% 2584

Other funds holding KLRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Nuveen's KLRA Position: Q2 2026 in Review

Nuveen opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 88,796 shares worth $1.96M. The stake represents ﹤0.01% of the portfolio and ranks #2584 among its holdings.

27 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Nuveen held 88,796 shares of Kailera Therapeutics worth $1.96M as of Q2 2026.
  • Kailera Therapeutics was a new Nuveen position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2584 holding.
  • 27 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.